AAN Guideline Evaluates Treatments for Children With Cerebral Palsy
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




AAN Guideline Evaluates Treatments for Children With Cerebral Palsy

ST. PAUL, Minn -- January 26, 2010 -- A new guideline from the American Academy of Neurology and the Child Neurology Society finds botulinum toxin type A to be an effective treatment for spasticity in children and adolescents with cerebral palsy, but the treatment poses some risk. The guideline is published in the January 26, 2010 print issue of the journal Neurology.

“Spasticity in children with cerebral palsy is best treated by a multidisciplinary medical and surgical team,” said lead guideline author Mauricio R. Delgado, MD, University of Texas Southwestern Medical Center, Dallas, Texas. “It is important that doctors, patients and caregivers together set a goal for measuring the success of medication use or any other spasticity treatment.”

Cerebral palsy is the most common cause of spasticity, and spasticity affects the majority of children with cerebral palsy. While cerebral palsy cannot be cured, treatment often improves a child’s capabilities.

After reviewing all available research on medication treatments for spasticity in cerebral palsy, the guideline found botulinum toxin type A is effective and generally safe, but there is some risk.

“In reviewing this drug for treatment of spasticity in children, the US Food and Drug Administration is investigating isolated cases of generalised weakness following use of botulinum toxin type A for spasticity,” said Dr. Delgado.

The guideline also recommends the drug diazepam be considered for short-term treatment of spasticity, although generalised side effects may occur. The drug tizanidine may also be considered, but there is risk of liver toxicity. For several other treatments, the authors determined that there was insufficient evidence to make a recommendation and encouraged additional research in this area.

“There is an urgent need for more research to establish the effectiveness of the current treatments for generalised spasticity and to find additional, safer and more effective medications,” said Dr. Delgado.

SOURCE: American Academy of Neurology

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities